EMA Approved ATMPs Advanced Therapy Medicinal Products (ATMPs) approved by European Medicines Agency (EMA). Name Developer Indication Approval Date Status Zynteglo Bluebird bio Feta-thalassemia Jun-19 Conditional Approved Luxtuma Spark Therapeautics Retinal dystrophy Mar-19 Approved Yescarta kite pharma B-cell lymphoma Aug-18 Approved Alofisel TiGenix Perianal fistulas in Crihn's disease Mar-18 Approved Spherox CO.DON Cartilage defects in the knee May-17 Approved Zalmoxis MolMed Stem cell transplantation for blood cancer Jun-16 Approved Strimvelis GSK ADA-SCID Apr-16 Approved lmlygic Amgen Melanoma Oct-15 Approved Holoclar Chiesi Limbal stem cell deficiency in the eyes Mar-15 Approved Provenge Dendreon Metastatic prostate cancer Oct-13 Withdrawn in 2015 MAXI Vericel Cartilage defects in the knee Jul-13 Withdrawn in 2014 Glybera uniQure Lipoprotein lipase deficiency Nov-12 Withdrawn in 2017 Chondrocelect TiGenix Cartilage defects Nov-09 Withdrawn in 2016 To get a quote for the products or to place an order, please email Sales@2BScientific.com.